Novartis AG : Gets a Buy rating from Deutsche Bank - marketscreener.comNovartis AG : Gets a Buy rating from Deutsche Bank marketscreener.com
Preparing for Novartis showdown, Curium touts value of radiopharma supply resiliency - BioSpacePreparing for Novartis showdown, Curium touts value of radiopharma supply resiliency BioSpace
News on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026 - Endpoints NewsNews on AstraZeneca, Cytokinetics, Novartis and more — what to look out for at ESC 2026 Endpoints News
Novartis stock holds a premium as cardiovascular data build investor interestNovartis AG (ISIN CH0012005267) stock is drawing renewed attention in August 2026 as investors balance a valuation premium against expectations for upcoming pivotal cardiovascular data and recent ...
Novartis (SWX:NOVN) Stock Could Trade Below Fair Value Despite Entresto Patent Win - Yahoo FinanceNovartis (SWX:NOVN) Stock Could Trade Below Fair Value Despite Entresto Patent Win Yahoo Finance
How Novartis optimized its supply chain - EYHow Novartis optimized its supply chain EY
Novartis (SWX:NOVN) Lines Up Pivotal Cardiovascular Data For ESC 2026Novartis (SWX:NOVN) plans to present late breaking data from multiple pivotal cardiovascular studies at the 2026 European Society of Cardiology Congress. The presentations include head to head Phase ...
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play - 24/7 Wall St.Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play 24/7 Wall St.
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent - ReutersNovartis defeats UK court bid to invalidate blockbuster drug Entresto patent Reuters
In surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment - STATIn surprise decision, FDA rejects radiopharma therapy expected to rival Novartis treatment STAT
Cognizant bags IT operations deal from NovartisCognizant secures a five-year AI-driven IT operations deal with Novartis to enhance efficiency and technology integration.
Natco Pharma challenges Novartis ribociclib patent at Delhi High CourtNatco Pharma has approached the Delhi High Court, contesting the Indian Patent Office's decision to grant Novartis a second patent for its breast cancer drug ribociclib.
Novartis Enrolled First Participant in Phase 3 PRESERVE Clinical Trial for Experimental PSP-RS Treatment - AFTD - The Association for Frontotemporal DegenerationNovartis Enrolled First Participant in Phase 3 PRESERVE Clinical Trial for Experimental PSP-RS Treatment AFTD - The Association for Frontotemporal Degeneration
Novartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer - Fierce PharmaNovartis' Pluvicto leaps ahead into earlier manifestation of prostate cancer Fierce Pharma
ChrysCapital acquires Novartis India, appoints Vikas Gupta as CEO - Business StandardChrysCapital acquires Novartis India, appoints Vikas Gupta as CEO Business Standard
Novartis to acquire UK ADC developer Myricx Bio - PharmaLiveNovartis to acquire UK ADC developer Myricx Bio PharmaLive
Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients - NovartisNovartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients Novartis
Novartis' new SMA gene therapy cleared in EU - pharmaphorumNovartis' new SMA gene therapy cleared in EU pharmaphorum
Novartis stumbles in challenge to Missouri discounted drug mandate - Courthouse NewsNovartis stumbles in challenge to Missouri discounted drug mandate Courthouse News
ASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture - Pharmaceutical TechnologyASCO 2026: Mixed SCLC result for Legend’s LB2102, Novartis expedites manufacture Pharmaceutical Technology